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Abstract
Background: Functional gastrointestinal disorders (FGIDs) are chronic or recurrent gastrointestinal symptoms
without structural or biochemical abnormalities. FGIDs are multifactorial conditions with different pathophysiologic
mechanisms including altered motility, visceral hyperalgesia, brain-gut disturbance, genetic, environmental and
psychological factors.
Although in most cases gastrointestinal symptoms are transient and with spontaneous resolution in infancy
multiple dietary changes and pharmacological therapy are often started despite a lack of evidence-based data. Our
aim was to update and critically review the current literature to assess the effects and the clinical appropriateness
of drug treatment in early (occurring in infants and toddlers) FGIDs.
Methods: We systematically searched the Medline and GIMBE (Italian Group on Medicine Based on Evidence)
databases, according to the methodology of the Critically Appraised Topics (CATs). We included reviews, clinical
studies, and evidence-based guidelines reporting on pharmacological treatments. Systematic reviews and
randomized controlled trials (RCTs) concerning pharmacologic therapies in children with early FGIDs were included,
and data were extracted on participants, interventions, and outcomes.
Results: We found no evidence-based guidelines or systematic reviews about the utility of pharmacological therapy
in functional regurgitation, infant colic and functional diarrhea. In case of regurgitation associated with marked
distress, some evidences support a short trial with alginate when other non pharmacological approach failed
(stepped-care approach). In constipated infants younger than 6 months of age Lactulose is recommended, whilst in
older ages Polyethylene glycol (PEG) represents the first-line therapy both for fecal disimpaction and maintenance
therapy of constipation. Conversely, no evidence supports the use of laxatives for dyschezia. Furthermore, we found
no RCTs regarding the pharmacological treatment of cyclic vomiting syndrome, but retrospective studies showed a
high percentage of clinical response using cyproheptadine, propanolol and pizotifen.
Conclusion: There is some evidence that a pharmacological intervention is necessary for rectal disimpaction in
childhood constipation and that PEG is the first line therapy. In contrast, for the other early FGIDs there is a lack of
well-designed high-quality RCTs and no evidence on the use of pharmacological therapy was found.
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Background
Functional gastrointestinal disorders (FGIDs) are defined
as a variable combination of chronic or recurrent gastro-
intestinal symptoms not explained by structural or bio-
chemical abnormalities [1].
To date, a complete understanding of the pathophysi-
ology of FGIDs remains elusive. Physiological, intrapsy-
chic, and sociocultural factors may amplify perception of
infant discomfort by care-givers. Hence, the symptoms
are often reported as severe, with impact on daily life ac-
tivities and frequent use of different empiric treatments.
It has been increasingly emphasized that FGIDs cannot
be solved with the biological management, but need the
biopsychosocial approach [2].
In the first few months of life FGIDs occur in up to
50 % of subjects with regurgitation and infantile colic
representing the two most common conditions that usu-
ally spontaneously resolve or improve by 6 to 8 months
of age. Other early (occurring in infants and toddlers)
FGIDs include dyschezia, infant rumination syndrome,
functional diarrhea, cyclic vomiting syndrome (CVS)
and functional constipation (Table 1).
Despite their favorable prognosis, such disorders are
often extensively investigated and treated with multiple
dietary changes and use of medications of uncertain bene-
fit. Successful management is complicated by an incom-
plete pathophysiologic understanding of the disorders.
Standard medical care consists of reassurance, education,
and dietary advices [2]. If this approach is not effective,
then pharmacological interventions are often prescribed.
Several drugs are used for treatment of FGIDs but no
evidence-based therapy is available so far. Therefore, a
systematic literature search was conducted on drug
treatment of early FGIDs.
The aim of this article was to critically summarize the
current evidences on the effects and the clinical appro-
priateness of pharmacological therapies in the treatment
of FGIDs in preschool children.
Methods
Data sources and search strategy
We systematically searched the Medline and GIMBE data-
bases using the following keywords: “gastric regurgitation”,
“gastroesophageal reflux”, “cyclic vomiting syndrome”, “in-
fant colic” “functional diarrhea”, “dyschezia”, “constipa-
tion”, “medication therapy management” or “treatment”,
from January 2005 to June 2015, without any lan-
guage restriction, limited to infant and preschool chil-
dren. Additional strategies for identifying studies
included the reference lists of review articles and in-
cluded studies. The search has been based on a
principle of hierarchical selection and has been con-
ducted at least in double and in blind.
In the hierarchical selection, summaries of evidence,
evidence-based guidelines (GL) and systematic reviews
(SR) were searched primarily. The research was then
completed according to theoretical saturation, with pri-
mary studies published after those included in the SR
and those considered relevant entered as retrieved.
Study selection
The target population of the interventions was repre-
sented by infant and toddlers with FGIDs, as defined by
the Rome III criteria.
The possible outcomes considered in studies and SR
were as follows: 1. The average duration and frequency
(daily, weekly or monthly) of symptoms, or the reduc-
tion rate of the average number or duration of episodes
2. The reduction in the use of drugs; 3. The cost-
effectiveness evaluation regarding number of pediatric
visits, number of hospital accesses, changes of milk for-
mulas, and the number of working days lost; 4. The dur-
ation of the child's sleep (min/day) whenever reported.
The intervention considered is the drug therapy, com-
pared with non-pharmacologic therapy and/or no therapy.
For regurgitation we included the ESPGHAN-
NASPGHAN [3] and NICE guidelines [4], a good quality
systematic review [5] and a cohort study [6].
For cyclic vomiting syndrome we included the
NASPGHAN 2008 Consensus Statement [7] and 3 re-
views [8–10].
For infant colic we considered the 2013 Consensus
[11] and a non-systematic review published in 2015 [12].
For functional diarrhea no systematic reviews or pri-
mary studies were found.
For infant dyschezia we consulted the ESPGHAN-
NASPGHAN combined guidelines on constipation [13],
a non-systematic review [11] and the Rome III Criteria
document [1].
Finally, for constipation we considered the evidence-
based 2014 ESPGHAN-NASPGHAN combined guide-
lines [13].
Data analyses
The analysis and the evaluation of the evidences have
been made in double, and in blind using checklists and
validated criteria.
Table 1 Functional gastrointestinal disorders in infants and
toddlers (according to Rome III classification)
Infant regurgitation
Infant rumination syndrome
Cyclic vomiting syndrome
Infant colic
Functional diarrhea
Infant dyschezia
Functional constipation
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The analysis and evaluation of guidelines were carried
out according to the following minimum criteria of val-
idity: multidisciplinary panel, search for evidence, and
grading of recommendations. SR analysis was performed
using the AMSTAR (Assessment of Multiple Systematic
Reviews) checklist [14].
For randomized studies, evaluation criteria for interven-
tion studies of the Users’ Guides to the Medical Literature
were used [15], while the analysis for other possible sources
of bias was completed using the Cochrane Collaboration
assessment of risk of bias validated instrument [16]. The
studies of accuracy and diagnostic validation have been val-
ued using the QUADAS 2 assessment tool [17].
Results
Table 2 summarizes the results of pharmacological ther-
apy in early FGIDs. There is a lack of evidences concern-
ing drug treatment in infant rumination syndrome,
functional diarrhea and infant dyschezia. The literature ev-
idences and main indications for pharmacological treat-
ment in the other early FGIDs are summarized below.
Infant regurgitation
Regurgitation is the passage of refluxed contents into
the pharynx or mouth. In young infants, daily regurgita-
tion is within the range of expected behaviors, and the
great majority of infants are thriving and do not develop
any disease [3]. Regurgitation reaches the peak at 4 to
6 months of age and decreases in frequency during
the second semester of life [18]. Although regurgita-
tion is a physiologic, frequent and spontaneously
recovering phenomenon in healthy infants, almost 25 % of
the parents are concerned and seek medical care [19].
Despite a wide use of drugs in infants with gastro-
esophageal reflux (GER) symptoms there are limited
data on clinical outcome in the first year of life and there
is no evidence that acid inhibitors or prokinetic agents
improve regurgitation [20–22].
For H2-receptor antagonists only one small trial (35
participants) comparing famotidine to placebo reported
results for infants and showed only a slightly reduced
frequency and volume of regurgitation [23]. Eleven pa-
tients had no-serious, possibly drug-related adverse ex-
periences including fussing or irritability, somnolence,
anorexia, headache, vomiting, hiccups, and candidiasis.
Guillet [24] first reported necrotizing enterocolitis in
newborns treated with H2 blockers. Another cohort
study [6] confirmed the increased risk in the newborns
treated with ranitidine compared to controls (OR = 5.5).
Two double-blind, placebo-controlled trials in irritable
infants with GER showed that both omeprazole and lan-
soprazole exert little effect on regurgitation and may be
associated with adverse events [25, 26]. Another ran-
domized single-blind study using esomeprazole for 8 days
in 50 infants with GER symptoms did not report a sig-
nificant clinical improvement [27]. The FDA reviewer
experience published in 2012 [28] pointed out that in
the 3 double-blinded and placebo-controlled clinical trials
testing esomeprazole, lansoprazole, and pantoprazole, there
were no statistically significant between-group differences.
The ESPGHAN-NASPGHAN guidelines do not rec-
ommend any pharmacological treatment in regurgitation
[3]. Acid inhibitors are restricted to GER-disease demon-
strated by investigations reserved to infants with alarm
symptoms [3, 5].
The NICE guidelines in 2015 do not indicate a routine
treatment in infants with regurgitation without marked
distress or “red flags” symptoms or signs. However, a short
trial with alginate (for 1–2 weeks) is considered when re-
gurgitation is associated with marked distress and other
non-pharmacological approach failed (stepped-care ap-
proach) [4].
A good quality systematic review [5] showed that the
studies published so far on the efficacy of alginate in
infants, present an underpowered population, and contro-
versial results. A recent randomized controlled trial in 64
full-term infants with GER symptoms, showed a statisti-
cally significant improvement in overall symptoms evalu-
ated through a validated questionnaire (I-GERQ) in the
group treated with Mg alginate plus simethicone compared
to the thickened formula or reassurance groups [29].
In conclusion there is no evidence that proton pump
inhibitors (PPI), Histamine2 Receptor Antagonist or
domperidone improves regurgitation whilst evidence of
efficacy of alginate is still limited. Safety concerns are
Table 2 Summary of evidences for Pharmacological Treatment
of FGIDs
FGID Results
Infant regurgitation Alginate may be considered if symptoms are
severe, associated with marked distress, and
other non-pharmacological measures failed
Infant rumination
syndrome
No evidence of pharmacological treatment
Cyclic vomiting
syndrome
No RCTs. Retrospective studies showed benefit
using cyproheptadine, propanolol and pizotifen
in prophylaxis. During the acute phase of
vomiting, intravenous infusion of glucoelctrolytic
solutions, ondasetron, lorazepam and acid
inhibitors are suggested.
Infant colic No evidence of pharmacological treatment
Functional diarrhea No evidence of pharmacological treatment
Infant dyschezia No evidence of pharmacological treatment
Constipation Lactulose is recommended for infants younger
than 6 months of age, whereas in older infants
and in children PEG with or without electrolytes
represents the first-line therapy for both fecal
disimpaction and maintenance.
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represented by neurological and cardiological effects for
prokinetic, and by diarrhea/constipation, headache, hyper-
gastrinemia and increased risk of infections for acid
inhibitors.
Cyclic vomiting syndrome
Cyclic vomiting syndrome (CVS) is a functional disorder
characterized by recurrent (3 attacks in 6 months or 5 at-
tacks in any time), individually stereotyped, transient
(from a few hours up to 10 days) episodes of intense nau-
sea and vomiting (at least 4 times/per hour for at least one
hour) [30]. Attacks are separated by periods (one week or
more) of complete well-being and no underlying path-
ology is recognised [30]. Despite the on-off pattern with
inter-critical wellness, the severity and frequency of the
acute emetic phases determine a negative impact of CVS
on quality of life, frequent hospital referral, extensive in-
vestigations and, in some cases, a significant impairment
of daily social activities and on school performance [31].
The incomplete knowledge of CVS pathophysiology
currently limits the specificity and efficacy of its treat-
ment. As reported in the NASPGHAN Guidelines [7]
and in 3 more recent reviews [8–10] antimigraine, anti-
emetic, and anticonvulsant molecules have been studied
in retrospective open-label trials for both prevention and
acute phase with different and individual benefits. No
prospective RCTs were identified.
As several precipitating (including psychological, physical,
infective and dietary) factors are identified in about 2/3 of
patients, a psychotherapeutic and nutritional support and
avoidance of individual triggers should be considered before
and in addition to pharmacological therapy.
Pharmacological prophylaxis is suggested if the crises
are frequent (more than 6 episodes/year) and/or severe
(requiring hospitalization) or disabling (lasting 3 days or
longer). In children aged less than 5 years antihistamines
such as cyproheptadine (0.25–0.5 mg/kg/day, twice per
day) and pizotifen (0.5–1.5 mg/day, once or twice per
day) are considered as “first-line therapy”. Propranolol
(0.25–1 mg/kg/day in 2–3 administrations) is suggested
as “second-line drug”, but is contraindicated in children
with asthma, diabetes, depression and heart disease.
Heart rate monitoring during the first days of therapy is
recommended in all patients as well as discontinuation:
tapering for 1–2 weeks. When the diagnosis for CVS is
confirmed and individualized therapy is initiated, low
dose first line drug should be progressively increased
every 1 to 4 weeks up to therapeutic range, for at least
2 cycles of vomiting episodes. If the medication is not ef-
fective in preventing the attack of episodes or if there
are significant adverse effects, the second-line drug or
combination therapy should be started.
Anti-emetic agents (ondansetron and granisetron),
anti-anxiety agents (lorazepam), and anti-migraine agents
(sumatriptan and zolmitriptan) have also been attempted
in prodromal phase. 5HT1B/1D receptor agonists (suma-
triptan) showed more efficacies in patients with family his-
tory of migraine. However, this drug is not approved for
use in children. Tricyclic anti-depressive agent amitriptyl-
ine was considered in the NASPGHAN guidelines in 2008
more effective as prophylactic drug in children older than
5 years [7]. To minimize side effects, the treatment is
commonly initiated at a single nighttime dose of 0.25–
0.5 mg/kg/day and increased weekly by 5 to 10 mg until
1.0–1.5 mg/kg. The risk of ventricular arrhythmias is
reduced by monitoring the QTc interval (to maintain
it <460 msec) before and after reaching the targeted
dose. Other side effects reported were constipation,
sedation and behavioral changes [8–10].
The benefit of oral erythromycin (20 mg/kg/day) as a
prokinetic agent, or anti-epileptic drugs such as valproic
acid and phenobarbital reported in initial trials was not
confirmed by other authors [8–10].
The incapacity of increasing the energy production re-
quired during stress conditions, as a consequence of mu-
tations of mtDNA, predisposes patients to the beginning
of a vomit cycle and perpetuates the dysfunction of auto-
nomic nervous system neurons [32]. Retrospective stud-
ies suggest the use of mitochondrial supplements such
as L-carnitine (50-100 mg per day divided into 2 or 3
doses to a maximum of 1 g three times a day) and coen-
zyme Q-10 (10 mg per kg per day in two or three di-
vided doses up to a maximum of 100 mg three times a
day). However, there is still insufficient data to recom-
mend their use in all children to prevent or reduce the
length and gravity of the cyclic vomit episodes [7–10].
During the acute phase of vomiting, intravenous infu-
sion of glucoelctrolytic solutions (with 10 % dextrose to
terminate ketosis) to prevent dehydration and electrolyte
imbalance,antiemetic drugs (5-HT3 receptor antagonist
Ondasetron at 0.3–0.4 mg/kg/dose every 6 h if neces-
sary, with an upper limit of 20 mg/dose), sedatives, such
as lorazepam (0.05–1 mg/kg per dose every 6 h) and
acid inhibitors to manage epigastric pain and prevent
esophageal damage are suggested [7, 33].
A quiet, dark room is a non-stimulating environment
that will help patients sleep.
Infant colic
Infantile colic was originally defined by Wessel as crying
lasting three or more hours a day, at least 3 days a week
and for at least 3 weeks [34]. According to Rome III
Criteria infantile colics are defined as irritability paroxysms
with fussiness or crying that starts and ends without clear
reasons, lasting at least 3 h a day, 3 days a week, for at least
one week, in healthy, well fed and thriving babies [2].
Numerous hypotheses have been generated and mul-
tiple etiologies have been proposed to explain infant
Salvatore et al. Italian Journal of Pediatrics  (2016) 42:68 Page 4 of 8
colic, leading to a variety of possible treatments. There are
no uniform criteria for a specific therapeutic approach
and no medication has definitively proved to be beneficial.
There are neither evidence-based recommendations
from GL nor dedicated SR.
The 2013 Consensus [11] and the review article by
Vandenplas et al. in 2015 [12] included 6 studies evaluating:
simethicone (anti-foaming agent), simethicone-lactase,
cimetropium bromide (anticholinergic antimuscarinic anti-
spasmodic molecule), dicycloverine (anti-cholinergic agent),
trimebutine (weak opioid and antimuscarinic effects), and
PPIs. None of the above treatment showed a significant ef-
fect and some of them, such as dicyclomine [35] and cime-
tropium, can cause potentially serious adverse reactions.
A recent SR including 5 randomized controlled trials
(and 430 infants enrolled) did not support the use of PPIs
to decrease infant crying and irritability and highlighted
related side effects specifically increased risk of gastro-
intestinal and/or respiratory tract infections [36].
Two studies found a comparable decrease in crying dur-
ation in infants given simethicone or placebo [37, 38].
Drugs with antispasmodic activity are commonly used,
based on the assumption that contractions of the intes-
tinal smooth muscles cause colic. Dicyclomine was more
effective than placebo in three trials [39–41], but danger-
ous side effects were described, such as respiratory symp-
toms, seizures, syncope, pulse rate fluctuations, muscular
hypotonia, and even coma that contraindicate its use in
infants [42].
Cimetropium bromide was reported to be more effective
than placebo in reducing the duration of crying but leth-
argy, motion sickness and somnolence may occur [43].
Constipation
The first step in managing functional constipation in in-
fants is to educate and reassure the parents [13]. In infants
younger than 6 months of age glycerine suppositories can
be helpful if rectal emptying is necessary to provide acute
relief whilst lactulose is recommended as maintenance
therapy [12].
In infants older than 6 months, several studies evalu-
ated the efficacy and safety of polyethylene glycol (PEG),
both for fecal disimpaction and for maintenance therapy
[44, 45]. PEG is an unabsorbable compound and is not
digested by colonic bacteria. Its mechanism of action is
increasing osmotic load in the large intestine, which re-
sults in expansion of stool volume [46].
Successful disimpaction occurred in 75–92 % of chil-
dren after 3–6 consecutive days, with the most effective
dose being 1.0–1.5 g/kg per day [46]. A RCT showed
that the use of oral PEG solution (1–1.5 gr/kg/die) for 6
consecutive days has the same efficacy of retrograde en-
emas. Bekkali et al demonstrated that successful disim-
paction was achieved in 80 % of the children using
retrograde enemas once daily and in 68 % of children
using oral PEG solution for 6 consecutive days [47].
PEG with or without electrolytes is safe and its collat-
eral effects, as diarrhea and abdominal pain, are deter-
mined by its mechanism of action. In a prospective
observational study, Pashankar et al failed to find any
side effects following PEG therapy [48].
Once the impaction has been removed, the treatment
focuses on the prevention of recurrence. The main
pharmacological agents are osmotic and stimulant laxa-
tives. Good quality clinical trials are lacking on effective-
ness of stimulant laxatives as maintenance therapy of
childhood constipation.
Lactulose is an unabsorbable, osmotically active carbo-
hydrate, which drags water into the gut, keeps the stools
soft and facilitates their passage avoiding pain. Two ran-
domized controlled trials comparing lactitol and lactulose
found that both are equally effective in increasing stool
frequency and normalizing stool consistency [49–51].
Candy et al., in a randomized, double-blind study,
noted that PEG with electrolytes was more effective
compared to lactulose in increasing defecation frequency
in children with intractable constipation [45].
Loening-Baucke, comparing PEG without electrolytes
with milk of magnesia, showed that no difference was
found [52]. In another randomized study, PEG and milk of
magnesia were equally effective in the long-term treatment
of children with constipation and fecal incontinence [53].
Evidence does not support the use of mineral oil,
which could lead to a risk of lipoid pneumonia, due to
lung aspiration.
The 2014 ESPGHAN-NASPGHAN combined guide-
lines state that PEG and enemas are equally effective for
fecal disimpaction. PEG administered orally is associated
with a higher frequency of fecal incontinence during
treatment of the fecal impaction compared with enema;
however, based on the argument that PEG can be ad-
ministered orally, the working group decided that PEG
is to be preferred (1.1.5 g/kg/die) [13]. The use of PEG
with or without electrolytes is recommended as first-line
maintenance treatment and the starting dose is 0.4 g/kg/
day. PEG resulted better than lactulose, milk of magnesia
and mineral oil [13]. The use of enemas for maintenance
therapy is not recommended in children with constipa-
tion. Glycerin suppositories can be considered for occa-
sional use in disimpaction [13].
Discussion
Functional symptoms during childhood may be related to
normal development (e.g., infant regurgitation), or to a mal-
adaptive behavioral response to internal or external stimuli
(e.g., in functional constipation, retention of feces can be
considered as a “learned response” to painful defecation or
to forced toilet training).
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Physiological, intrapsychic, and sociocultural factors
amplify the perception of these symptoms so they may
be experienced as severe, troublesome, or threatening,
with subsequent impact on family quality of life, daily
activities and medical care [54].
Over the last few years a great bulk of evidence has
shown the crucial role of the so-called brain-gut axis in
the pathophysiology of gastrointestinal diseases [55].
Through this bidirectional communication system, sig-
nals from the brain can modulate various intestinal func-
tions (motility, secretion, blood flow, and gut-associated
immunity) and conversely, visceral messages from the
gastrointestinal tract can influence brain activity. Bidir-
ectional signals between the gut and the brain are regu-
lated at neural, immunological and hormonal levels, and
involve the hypothalamic-pituitary-adrenal axis and the
enteric microbiota. The neural pathways include the
central nervous system, the sympathetic and parasympa-
thetic arms of the autonomic nervous system and the
enteric nervous system [56, 57]. Alteration of the neural-
gut cross-talk and network may be involved in the
pathophysiology of functional and inflammatory gastro-
intestinal disorders.
Despite recent advances in pathophysiology, there is
still no biological specific marker of FGIDs. Therefore,
the diagnosis is currently clinically based from a set of
symptoms with exclusion of warning signs. It is also
known that FGIDs cannot be solved with the biological
management, but need the biopsychosocial approach.
According to this model, symptoms are both physiolo-
gically multi-determined and modifiable by sociocultural
and psychosocial influences.
An improved awareness and knowledge of FGIDs are
essential to help general practitioners and pediatricians
in the pharmacological and non pharmacological man-
agement of these frequent conditions.
Infants presenting with gastrointestinal problems such
as regurgitation, cyclic vomiting syndrome, infantile
colic and defecation problems often undergo a series of
unnecessary investigations and medical treatments [2].
In the last 2 decades, PPI prescriptions dramatically
increased in pediatric patients. As the use of acid-
suppressive medication has risen, many have questioned
the effectiveness and safety of these agents [58, 59]. Al-
though suppression is effective in the treatment of rare
acid-related symptoms or erosive esophagitis in children,
RCTs and SR have demonstrated a lack of efficacy of PPIs,
specifically in treating regurgitation or other GER symp-
toms in infants [60]. In regurgitation treatment, limited
data and the NICE guidelines support a short trial with al-
ginate if symptoms are severe, troublesome and non re-
sponsive to behavioral and dietetic modifications.
In functional constipation, lactulose is recommended
for infants younger than 6 months of age, whereas PEG
has been shown to be more effective in older children.
Particularly, when compared to other laxatives, PEG is
more active in increasing stool frequency and decreasing
difficulty in passing stools and thus represents the first-
line therapy for both fecal disimpaction and maintenance.
Conversely, no evidence supports the use of laxatives for
infant dyschezia.
We found no evidence-based GL or SR about the utility
of pharmacological therapy in infantile colic, rumination
and functional diarrhea. Moreover, no RCTs regarding the
pharmacological treatment of CVS are available, but retro-
spective studies showed a good (individual) clinical re-
sponse to drugs such as cyproheptadine, propanolol and
pizotifen in prohylaxis in young children. During the acute
phase of vomiting, intravenous infusion of glucoelctrolytic
solutions, ondasetron, lorazepam and acid inhibitors are
suggested.
Conclusion
Evidence supporting a pharmacological approach to
early FGIDs is scarce except than in constipation, thus
justifying caution when prescribing drugs to these pa-
tients. Further research is needed to clarify the under-
lying mechanisms of these disorders and the efficacy of
pharmacological treatments in early FGIDs.
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